^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tevimbra (tislelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage IB to III Non-small Cell Lung Cancer
Excerpt:
...EGFR mutational status should be tested in all non-squamous carcinoma, and only patients with non-EGFR-TKI sensitizing mutation (19del or L858R) are allowed....
Source:
Title:
148P - A Phase II Study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: first analysis
Published date:
12/02/2021
Excerpt:
17 pts (53.1%) harbored EGFR exon 19del, and 14 pts (43.8%) with exon 21 L858R. 17 pts (53.1 %) had progression on both 1st /2nd and 3rd EGFR-TKIs treatment. Favorable ORR was observed in all subgroups. This multicenter, single-arm, phase II study enrolled pts with EGFR sensitizing mutations who have failed prior EGFR-TKI therapies. Tislelizumab (tis)...Pts were treated with tis plus carboplatin and nab-paclitaxel Q3W for up to 4 cycles, followed by tis plus pemetrexed maintenance therapy.
Secondary therapy:
pemetrexed; carboplatin + albumin-bound paclitaxel
Trial ID:
